The impact of metformin in chronic kidney disease-mineral and bone disorder
Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a disorder of mineral and bone metabolism due to chronic kidney disease (CKD). Bone disease and mortality are more common in patients with CKD. In addition of antidiabetic properties of metformin (MET), it possesses anti-inflammatory, ant...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Society of Diabetic Nephropathy Prevention
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/9185892ed5da41f999553db70b8a8210 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:9185892ed5da41f999553db70b8a8210 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:9185892ed5da41f999553db70b8a82102021-11-17T08:13:57ZThe impact of metformin in chronic kidney disease-mineral and bone disorder2345-420210.34172/npj.2021.02https://doaj.org/article/9185892ed5da41f999553db70b8a82102021-01-01T00:00:00Zhttps://jnephropharmacology.com/PDF/npj-8316https://doaj.org/toc/2345-4202Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a disorder of mineral and bone metabolism due to chronic kidney disease (CKD). Bone disease and mortality are more common in patients with CKD. In addition of antidiabetic properties of metformin (MET), it possesses anti-inflammatory, anti-fibrotic properties and increases the markers of osteogenic effects. Therefore, it improves bone quality and decreases the risk of fractures in patients with type 2 diabetes. Metformin can also inhibit arterial calcification, maintain calcium-phosphorus balance, decrease cellular infiltration, fibrosis, and inflammation in kidney. Based on evidence, the prevalence of lactic acidosis due to metformin in patients with type 2 diabetes (T2D) and renal dysfunction is lower compared to other oral antidiabetic agents. Metformin decreases all-cause mortality in patients with diabetic nephropathy. The administration of metformin showed no difference in the prevalence of lactic acidosis in patients with T2D who had normal, mild, moderate, or severe renal dysfunction. Therefore, metformin can be used in patients with significant CKD to inhibit CKD-MBD due to its osteogenic effects.Rohollah MasumiRamin TolouianAudrey TolouianLeila MohmoodniaSociety of Diabetic Nephropathy Prevention articlemetforminchronic kidney disease-mineral and bone disorderbone fractureTherapeutics. PharmacologyRM1-950Diseases of the genitourinary system. UrologyRC870-923ENJournal of Nephropharmacology, Vol 10, Iss 1, Pp e02-e02 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
metformin chronic kidney disease-mineral and bone disorder bone fracture Therapeutics. Pharmacology RM1-950 Diseases of the genitourinary system. Urology RC870-923 |
| spellingShingle |
metformin chronic kidney disease-mineral and bone disorder bone fracture Therapeutics. Pharmacology RM1-950 Diseases of the genitourinary system. Urology RC870-923 Rohollah Masumi Ramin Tolouian Audrey Tolouian Leila Mohmoodnia The impact of metformin in chronic kidney disease-mineral and bone disorder |
| description |
Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a disorder of mineral and bone metabolism due to chronic kidney disease (CKD). Bone disease and mortality are more common in patients with CKD. In addition of antidiabetic properties of metformin (MET), it possesses anti-inflammatory, anti-fibrotic properties and increases the markers of osteogenic effects. Therefore, it improves bone quality and decreases the risk of fractures in patients with type 2 diabetes. Metformin can also inhibit arterial calcification, maintain calcium-phosphorus balance, decrease cellular infiltration, fibrosis, and inflammation in kidney. Based on evidence, the prevalence of lactic acidosis due to metformin in patients with type 2 diabetes (T2D) and renal dysfunction is lower compared to other oral antidiabetic agents. Metformin decreases all-cause mortality in patients with diabetic nephropathy. The administration of metformin showed no difference in the prevalence of lactic acidosis in patients with T2D who had normal, mild, moderate, or severe renal dysfunction. Therefore, metformin can be used in patients with significant CKD to inhibit CKD-MBD due to its osteogenic effects. |
| format |
article |
| author |
Rohollah Masumi Ramin Tolouian Audrey Tolouian Leila Mohmoodnia |
| author_facet |
Rohollah Masumi Ramin Tolouian Audrey Tolouian Leila Mohmoodnia |
| author_sort |
Rohollah Masumi |
| title |
The impact of metformin in chronic kidney disease-mineral and bone disorder |
| title_short |
The impact of metformin in chronic kidney disease-mineral and bone disorder |
| title_full |
The impact of metformin in chronic kidney disease-mineral and bone disorder |
| title_fullStr |
The impact of metformin in chronic kidney disease-mineral and bone disorder |
| title_full_unstemmed |
The impact of metformin in chronic kidney disease-mineral and bone disorder |
| title_sort |
impact of metformin in chronic kidney disease-mineral and bone disorder |
| publisher |
Society of Diabetic Nephropathy Prevention |
| publishDate |
2021 |
| url |
https://doaj.org/article/9185892ed5da41f999553db70b8a8210 |
| work_keys_str_mv |
AT rohollahmasumi theimpactofmetformininchronickidneydiseasemineralandbonedisorder AT ramintolouian theimpactofmetformininchronickidneydiseasemineralandbonedisorder AT audreytolouian theimpactofmetformininchronickidneydiseasemineralandbonedisorder AT leilamohmoodnia theimpactofmetformininchronickidneydiseasemineralandbonedisorder AT rohollahmasumi impactofmetformininchronickidneydiseasemineralandbonedisorder AT ramintolouian impactofmetformininchronickidneydiseasemineralandbonedisorder AT audreytolouian impactofmetformininchronickidneydiseasemineralandbonedisorder AT leilamohmoodnia impactofmetformininchronickidneydiseasemineralandbonedisorder |
| _version_ |
1718425810832982016 |